Lonza Disinfectant Ingredients Secure U.S. EPA Approval for Surface Use Against SARS-CoV-2 Virus Donnerstag, 30. Juli 2020 - 19:40
Lonza Disinfectant Ingredients Secure U.S. EPA Approval for Surface Use Against SARS-CoV-2 Virus
• More than 10 Lonza products approved to kill SARS-CoV-2 on hard surfaces
• Unprecedented demand for quat-based disinfectant products during COVID-19 pandemic
• Lonza has committed to increasing production to meet the surge in demand for hygiene products to stop the spread of SARS-CoV-2
Morristown, NJ (USA), 30 July 2020– This week, the U.S. Environmental Protection Agency (EPA) announced that several Lonza products have been tested directly against the novel coronavirus, SARS-CoV-2, and have been specifically approved to kill the virus on hard surfaces.
The approved Lonza products include:
- Lonzagard® RCS-256 Plus (EPA Reg. No. 6836-349)
- Lonzagard® RCS-128 Plus (EPA Reg. No. 6836-348)
- Lonzagard® S-21 (EPA Reg. No. 6836-75)
- Lonzagard® R-82 (EPA Reg. No. 6836-78)
- Lonzagard® S-21F (EPA Reg. No. 6836-140)
- Lonzagard® S-18 (EPA Reg. No. 6836-77)
- Lonzagard® S-18F (EPA Reg. No. 6836-136)
- Lonzagard® R-82F (EPA Reg. No. 6836-139)
- Lonzagard® DC-103 (EPA Reg. No. 6836-152)
- Lonzagard® R-82G (EPA Reg. No. 6836-381)
- Lonzagard® RCS-256 (EPA Reg. No. 6836-346)
- Lonzagard® RCS-128 (EPA Reg. No. 6836-347)
“We have seen unprecedented demand for quat-based disinfectant products and we know the important role many Lonza products play in the fight against the coronavirus pandemic,” said Ernesto Lippert, Lonza Vice President of Strategic Development & Advocacy. “We are pleased the EPA has approved these products as effective against the SARS-CoV-2 virus and commit to working to continue to meet the incredible demand for these critical products.”
For more information on Lonza’s work in Microbial Control Solutions visit our website here: https://microbialmanagement.lonza.com
About Lonza
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment. Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries.
With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
Lonza Contact Details
Media:
Victoria Morgan
Head of Corporate Communications
+41 79 599 6260
victoria.morgan@lonza.com
Investor Relations:
Dirk Oehlers
VP - Investor Relations
+41 79 421 1609
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
